CLINICAL_TRIALS
trial_result
· 2024-04-19
Clinical Trial Update: Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab [Phase 2]
Summary
Phase 2 trial evaluating apremilast 30 mg twice daily in combination with dupilumab for atopic dermatitis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tufts Medical Center | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-04-19